- Home
- BIIB vs ERIE Comparison
BIIB vs ERIE Comparison
Compare BIIB & ERIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ERIE
- Stock Information
- Founded
- BIIB 1978
- ERIE 1925
- Country
- BIIB United States
- ERIE United States
- Employees
- BIIB N/A
- ERIE N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ERIE Specialty Insurers
- Sector
- BIIB Health Care
- ERIE Finance
- Exchange
- BIIB Nasdaq
- ERIE Nasdaq
- Market Cap
- BIIB 25.1B
- ERIE 21.7B
- IPO Year
- BIIB 1991
- ERIE 1995
- Fundamental
- Price
- BIIB $160.63
- ERIE $440.56
- Analyst Decision
- BIIB Buy
- ERIE
- Analyst Count
- BIIB 25
- ERIE 0
- Target Price
- BIIB $260.48
- ERIE N/A
- AVG Volume (30 Days)
- BIIB 1.7M
- ERIE 160.7K
- Earning Date
- BIIB 10-30-2024
- ERIE 10-31-2024
- Dividend Yield
- BIIB N/A
- ERIE 1.16%
- EPS Growth
- BIIB 10.05
- ERIE 39.56
- EPS
- BIIB 11.06
- ERIE 12.10
- Revenue
- BIIB $9,607,500,000.00
- ERIE $3,688,692,000.00
- Revenue This Year
- BIIB N/A
- ERIE $18.45
- Revenue Next Year
- BIIB N/A
- ERIE $11.54
- P/E Ratio
- BIIB $14.52
- ERIE $36.40
- Revenue Growth
- BIIB N/A
- ERIE 17.03
- 52 Week Low
- BIIB $153.62
- ERIE $295.27
- 52 Week High
- BIIB $268.30
- ERIE $547.00
- Technical
- Relative Strength Index (RSI)
- BIIB 33.97
- ERIE 51.47
- Support Level
- BIIB $156.09
- ERIE $403.09
- Resistance Level
- BIIB $160.63
- ERIE $430.58
- Average True Range (ATR)
- BIIB 3.99
- ERIE 9.27
- MACD
- BIIB 0.46
- ERIE 6.21
- Stochastic Oscillator
- BIIB 31.52
- ERIE 87.48
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. Erie Indemnity's management fee is typically 25% of the Exchange's premiums, and this accounts for all of Erie Indemnity's revenue. The company operates exclusively in the United States.